Clinical Trial

A Study to Assess NEU-627 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1, randomized, double-blind, placebo-controlled study of NEU-627 designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-27; most recent amendment 2026-01-13.
Status change: Recruiting → Completed 2026-01-13
Status change: Not Yet Recruiting → Recruiting 2025-06-10
Trial Details
NCT Number NCT06900751
Lead Sponsor Neuron23 Inc.
Conditions Healthy
Enrollment 74 participants
Start Date 2025-06-02
Primary Completion 2025-10-28 (estimated)
Study Completion 2025-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-15